Facial and perioral primary impetigo: a clinical study

Impetigo is the most common skin infection in children. The face, especially the perioral region, is one of the most frequently involved areas. Impetigo is a disease that interests the pediatric dentist, as it poses significant problems in its differential diagnosis from other conditions. Sixteen otherwise healthy children were examined suffering from facial and perioral impetigo. The typical clinical appearance was scattered, painless, slightly pruritic erosions covered by “honey-colored” crusts. In 4 children impetigo was localized in the facial and perioral area, whereas in all other cases lesions were diffused in perioral area and several regions throughout the body. Four children exhibited neck lym-phadenopathy and one had mild fever. The treatment of impetigo included the application of topical measures with the systemic antibiotic chemotherapy.

1. Nevil BW, Damm DD, White DII. Color atlas of clinical oral pathology. 2nd ed. BC Becker; pp. 116, 2003.

2. Fitzpatrick TB, Johnson RA, Wolff K, Suurmod D. Impetigo and Ecthyma: Color atlas & synopsis of clinical dermatology. 4th ed. McGraw-Hill Companies; 2001: 586-591, 2001.

3. Brown J, Shriner DL, Schwartz RA, et al. Impetigo: an update. Int J Derm 42: 251-255, 2003.

4. Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo II: Etiologic agents and bacterial of impetigo II. Etiologic agents and bacterial interactions. J Clin Invest 51: 2863- 2871, 1972.

5. Euvrad S, Kanitakis J, Cochat P, et al. Skin diseases in children with organ transplants. JAAD 44: 932-939, 2001.

6. Hogewoning AA, Goettsch W, van Loveren H, et al. Skin infec-tions in renal transplant recipients. Clin Transplant 15: 32-38, 2001.

7. Whitworth JM, Janniger CK, Oleske JM, Schwartz RA. Cutaneous manifestations of childhood acquired immunodefi-ciency syndrome and human immunodeficiency virus infection. Cutis 55: 62-72, 1995.

8. SahI WJ, Mathewson RJ. Common facial skin lesions in children. Quintessence mt 24: 475-48 1, 1993.

9. Nanda S, Reddy BSN, Ramji S, Pandhi D.Analytical study of pus-tular eruptions in neonates. Ped Dermatol 19: 210-215, 2002.

10. Habif T. Clinical dermatology. A color guide to diagnosis and therapy. 3rd ed. Mosby, pp 236-241, 1996.

11. Sanfilippo AM, Barrio V. Kulp-Shorten C, et al. Common pedi-atric and adolescent skin conditions. J Ped Adol Gynecol 16: 269-283, 2003.

12. Scully C, Welbury R, Flaitz C, et a! A color atlas of orofacial health & disease in children and adolescents. 2nd ed. Dunitz, p 158, 2002.

13. Koning S, van Belkum A, Snijders S. Impetigo in children is asso-ciated with strains harboring genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resis-tance plasmid pSK41. J Clin Microbiol 41:3017-3021, 2003.

14. Hanakawa Y, Schechter NM, Lin C, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 110: 53-60, 2002.

15. Hanakawa Y, Selwood T, Woo D, et al. Calcium-dependent con-formation of desmoglein 1 is required for its cleavage by exfolia-tive toxin. J Invest Dermatol 12 1: 383-389, 2003.

16. Sakurai S, Suzuki H, Saito S, et al. New evidence that the Tyr-157 and Tyr-159 residues of staphylococcal exfoliative toxin B are essential for its toxicity. Microbiol Immunol 42: 829-836, 1998.

17. Gravet A, Couppie P. Meunier O, et al. Staphylococcus aureus isolated in cases of impetigo produces both epidermolysin A or B and LukE-LukD in 78% of 131 retrospective and prospective cases. J Clin Microbiol 46: 5 1-53, 2001.

18. Akiyama H, Yamasaki O, Kanzaki H, et al. Streptococci isolated from various skin lesions: the interaction with Staphylococcus aureus strains. J Dermatol Sci, 19: 17-22, 1999.

19. Scaramuzzino DA, McNiff JM, Bessen DE. Humanized in vivo model for streptococcal impetigo. Infect Immun 68: 2880-2887, 2000.

20. Kalia A, Spratt BG, Enright MC, et al. Influence of recombina-tion and niche separation on the population genetic structure of the pathogen Streptococcus pyogenes. Infect Immunol 70: 1971-1983, 2002.

21. Darmstadt G, Fleckman P, Jonas M, et al. Differentiation of cul-tured keratinocytes promotes the adherence of Streptococcus pyogenes. J Clin Invest 101: 128-136, 1999.

22. Darmstadt G, Mentele L, Fleckman P, et al. Role of Keratinocyte Injury in Adherence of Streptococcus pyogenes. Infect Immun 67: 6707-6709, 1999.

23. Svensson MD, Sjobring U, Luo F, et al. Roles of the plasminogen activator streptokinase and the plasminogen-associated M pro-tein in an experimental model for streptococcal impetigo. Microbiol 148: 3933-3945, 2002.

24. Darmstadt GL, Fleckrnan P, Rubens CE. Tumor necrosis factor-alpha and interleukin-lalpha decrease the adherence of Streptococcus pyogenes to cultured keratinocytes. J Infect Dis 180: 1718-1721, 1999.

25. Wannamaker LW. Differences between streptococcal infections of the throat and of the skin. N Engi J Med 282: 23-3 1, 1970.

26. Ardiles L, Ramirez P, Moya P, et al. Anticardiolipin antibodies in acute poststreptococcal g!omerulonephritis and streptococcal impetigo. Nephron 83: 47-52, 1999.

27. Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann 22: 235-240, 1993.

28. Koning S, van der Wouden JC. Fusidic acid cream in the treat-ment of impetigo in general practice: double blind randomized placebo controlled trail. Br Med J 26: 203-206, 2002.

29. Nishijim S, Ohshima S, Higashida T, et al. Antimicrobial resis-tance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000. Int J Derm 42: 23-25, 2003.

30. Christensen OB, Anehus S. Hydrogen peroxide cream: an alter-native to topical antibiotics in the treatment of impetigo conta-giosa. Acta Derm Venereol 74: 460-462, 1994.

31. Sharquie KE, al-Turfi IA, al-Salloum SM. The antibacterial activ-ity of tea in vitro and in vivo (in patients with impetigo conta-giosa). J Dermatol 27: 706-7 10, 2000.